Compare DV & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | ZYME |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2022 |
| Metric | DV | ZYME |
|---|---|---|
| Price | $13.31 | $27.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $16.37 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 4.5M | 499.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $748,291,000.00 | $105,965,000.00 |
| Revenue This Year | $12.68 | $183.10 |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | $110.83 | ★ N/A |
| Revenue Growth | 13.92 | ★ 38.87 |
| 52 Week Low | $7.61 | $13.60 |
| 52 Week High | $16.44 | $29.75 |
| Indicator | DV | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 73.09 |
| Support Level | $10.03 | $22.10 |
| Resistance Level | $13.36 | $29.75 |
| Average True Range (ATR) | 0.08 | 1.10 |
| MACD | -0.01 | 0.57 |
| Stochastic Oscillator | 97.01 | 99.52 |
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.